<div id="readability-page-1"><div id="block-content"> Zentalis Pharmaceuticals has dosed the first patient in Aspenova, a global phase III trial evaluating the oral WEE1 inhibitor azenosertib against investigator’s choice chemotherapy in Cyclin E1-positive platinum-resistant ovarian cancer (PROC).Platinum-resistant ovarian cancer remains a difficult treatment setting. Standard nonplatinum options enerally offer modest response rates and limited progression-free survival, while cumulative toxic effects and prior bevacizumab or PARP inhibitor exposure can further narrow choices.2,3Current NCCN guidance lists sequential single-agent therapy as a common approach in platinum-resistant disease, underscoring the need for better-tolerated and more active therapies for molecularly defined subsets.3The study is intended as a confirmatory trial as part of a development program including the registration-intended phase II Denali study and could help define whether biomarker selection for WEE1 inhibition improves outcomes in a setting where treatment options remain limited.1,4“Dosing the first patient in the Aspenova Phase III clinical trial represents a significant milestone in our development of azenosertib for patients with platinum-resistant ovarian cancer,” said Ingmar Bruns, MD, chief medical officer of Zentalis, in the company’s release.1Aspenova enrolled approximately 420 patients with Cyclin E1-positive PROC and randomized them to azenosertib 400 mg once daily on a 5-days-on, 2-days-off schedule or to single-agent chemotherapy selected by the investigator: paclitaxel, pegylated liposomal doxorubicin, gemcitabine, or topotecan.1The primary end point of the trial was progression-free survival, with overall survival and overall response rate listed as key secondary end points. According to the company, the design was aligned with FDA as part of a potential accelerated approval pathway in which Denali could support an initial filing and Aspenova could serve as the confirmatory study.1The strategy reflects a familiar regulatory model in oncology, but it also raises operational and evidentiary requirements, as confirmation of benefit in a biomarker-defined subgroup will depend not only on efficacy, but also on reproducible assay performance across regions and sites. Zentalis says validation of its Cyclin E1 companion diagnostic assay is ongoing in both Denali and Aspenova.1Key limitations during this stage of testing includes, the absence of peer-reviewed data from Denali Part II, lack of disclosed safety tables for the selected dose, and uncertainty about how broadly the assay will perform in routine practice.Azenosertib is an investigational oral inhibitor of WEE1, a kinase involved in cell-cycle checkpoint control through regulation of CDK1 and CDK2.1 The biologic rationale for WEE1 inhibition in Cyclin E1-driven tumors is based on replication stress and checkpoint dependence, a concept that has supported broader development of WEE1-targeted therapies in ovarian and other solid tumors.4 However, clinical proof in this specific biomarker-selected population remains pending.Zentalis says an interim dose-confirmation analysis in Denali Part IIa favored the 400-mg 5:2 schedule over 300 mg 5:2 for response rate, with “comparable safety profiles,” but it did not disclose numerical efficacy or adverse event data.1 Without those details, the magnitude of potential benefit and tolerability relative to standard chemotherapy cannot yet be independently assessed.Fiona Simpkins, MD, professor at the University of Pennsylvania Perelman School of Medicine and lead investigator for Aspenova, said: “Cyclin E1-overexpressing ovarian cancers are associated with platinum-resistance and poor outcomes, representing a clinical unmet need.”Next steps include continued enrollment in Aspenova and completion of Denali Part II, which Zentalis expects a topline readout by the end of 2026.1<ol><li>Zentalis Pharmaceuticals. Zentalis Pharmaceuticals announces first patient dosed in ASPENOVA Phase 3 trial of azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer. GlobeNewswire. May 5, 2026. Accessed May 6, 2026. </li><li>Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase 3 trial. J Clin Oncol. 2014;32(13):1302-1308.</li><li>National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version current as of 2026. Accessed May 6, 2026.</li><li>Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280-304.</li></ol> </div></div>

ZNTL

LABU

ARKG

Zentalis Pharmaceuticals has initiated the Aspenova Phase III trial, dosing its first patient to evaluate azenosertib, an oral WEE1 inhibitor, against chemotherapy in Cyclin E1-positive platinum-resistant ovarian cancer. This trial aims to confirm whether biomarker selection enhances treatment outcomes in a challenging setting with limited options. Approximately 420 patients will be enrolled, with the primary endpoint being progression-free survival. The study aligns with FDA guidelines for potential accelerated approval, although key limitations include the absence of peer-reviewed data and safety information. Zentalis expects topline results from the Denali study by late 2026.

Pharmexec

ZeZentalis Pharma

iShares US Pharma

VanEck Biotech ETF

VG Health

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

<![CDATA[First Patient Dosed with Azenosertib in Aspenova Phase III Trial for Treatment of Ovarian Cancer]]>